157 related articles for article (PubMed ID: 12036913)
1. Effect of germ-line genetic variation on breast cancer survival in a population-based study.
Goode EL; Dunning AM; Kuschel B; Healey CS; Day NE; Ponder BA; Easton DF; Pharoah PP
Cancer Res; 2002 Jun; 62(11):3052-7. PubMed ID: 12036913
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
[TBL] [Abstract][Full Text] [Related]
3. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD
Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334
[TBL] [Abstract][Full Text] [Related]
4. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
DeMichele A; Martin AM; Mick R; Gor P; Wray L; Klein-Cabral M; Athanasiadis G; Colligan T; Stadtmauer E; Weber B
Cancer Res; 2003 Nov; 63(22):8051-6. PubMed ID: 14633738
[TBL] [Abstract][Full Text] [Related]
6. Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status.
Fourquet A; Stoppa-Lyonnet D; Kirova YM; Sigal-Zafrani B; Asselain B; ;
Am J Clin Oncol; 2009 Apr; 32(2):127-31. PubMed ID: 19307946
[TBL] [Abstract][Full Text] [Related]
7. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
Goffin JR; Chappuis PO; Bégin LR; Wong N; Brunet JS; Hamel N; Paradis AJ; Boyd J; Foulkes WD
Cancer; 2003 Feb; 97(3):527-36. PubMed ID: 12548593
[TBL] [Abstract][Full Text] [Related]
8. Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals--correlation with clinicopathological data.
Kataki A; Gomatos I; Pararas N; Armakolas A; Panousopoulos D; Karantzikos G; Voros D; Zografos G; Markopoulos C; Leandros E; Konstadoulakis M
Clin Genet; 2005 Apr; 67(4):322-9. PubMed ID: 15733268
[TBL] [Abstract][Full Text] [Related]
9. Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.
Hughes DJ; Ginolhac SM; Coupier I; Corbex M; Bressac-de-Paillerets B; Chompret A; Bignon YJ; Uhrhammer N; Lasset C; Giraud S; Hardouin A; Berthet P; Peyrat JP; Fournier J; Nogues C; Lidereau R; Muller D; Fricker JP; Longy M; Toulas C; Guimbaud R; Maugard C; Olschwang S; Yannoukakos D; Durocher F; Moisan AM; Simard J; Mazoyer S; Lynch HT; Szabo C; Lenoir GM; Goldgar DE; Stoppa-Lyonnet D; Sinilnikova OM
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):265-7. PubMed ID: 15668505
[TBL] [Abstract][Full Text] [Related]
10. Dinucleotide repeat polymorphisms of RAD51, BRCA1, BRCA2 gene regions in breast cancer.
Nowacka-Zawisza M; Brys M; Romanowicz-Makowska H; Kulig A; Krajewska WM
Pathol Int; 2008 May; 58(5):275-81. PubMed ID: 18429825
[TBL] [Abstract][Full Text] [Related]
11. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
Chetrit A; Hirsh-Yechezkel G; Ben-David Y; Lubin F; Friedman E; Sadetzki S
J Clin Oncol; 2008 Jan; 26(1):20-5. PubMed ID: 18165636
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews.
Raskin L; Lejbkowicz F; Barnett-Griness O; Dishon S; Almog R; Rennert G
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1617-23. PubMed ID: 19366906
[TBL] [Abstract][Full Text] [Related]
13. Association of BRCA2 polymorphism at codon 784 (Met/Val) with breast cancer risk and prognosis.
Ishitobi M; Miyoshi Y; Ando A; Hasegawa S; Egawa C; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2003 Apr; 9(4):1376-80. PubMed ID: 12684407
[TBL] [Abstract][Full Text] [Related]
14. Hereditary breast/ovarian cancer: clinicopathological characteristics and survival of BRCA2 positive and negative cases.
Syamala V; Syamala VS; Sreeja L; Raveendran PB; Vijayalekshmi RV; Sheeja VR; Santhi S; Kuttan R; Abraham EK; Ankathil R
J Exp Ther Oncol; 2008; 7(3):227-36. PubMed ID: 19066131
[TBL] [Abstract][Full Text] [Related]
15. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor (CAG)n and (GGC)n polymorphisms and breast cancer risk in a population-based case-control study of young women.
Suter NM; Malone KE; Daling JR; Doody DR; Ostrander EA
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):127-35. PubMed ID: 12582022
[TBL] [Abstract][Full Text] [Related]
17. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1.
Bau DT; Fu YP; Chen ST; Cheng TC; Yu JC; Wu PE; Shen CY
Cancer Res; 2004 Jul; 64(14):5013-9. PubMed ID: 15256476
[TBL] [Abstract][Full Text] [Related]
19. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy.
Golshan M; Miron A; Nixon AJ; Garber JE; Cash EP; Iglehart JD; Harris JR; Wong JS
Am J Surg; 2006 Jul; 192(1):58-62. PubMed ID: 16769276
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
